Recent price performance and business snapshot Dianthus Therapeutics (DNTH) has drawn investor attention after a strong period in the stock, with recent moves over the month and past 3 months ...
FDA Fast Track designation has been granted to CTx001 for Geographic Atrophy secondary to Age-related Macular Degeneration CTx001 is an investigational AAV-based gene therapy designed to modulate ...
Dianthus Therapeutics, a clinical-stage biotechnology company, has appointed John C. King as Chief Commercial Officer, bringing over 25 years of experience in the biotechnology industry, particularly ...
NEW YORK and WALTHAM, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of ...
CTx001 is an investigational AAV-based gene therapy designed to modulate multiple pathways of the complement system Opti-GAIN is a first-in-human trial to evaluate the safety, tolerability, and ...
In the preceding three months, 4 analysts have released ratings for Dianthus Therapeutics DNTH, presenting a wide array of perspectives from bullish to bearish. Summarizing their recent assessments, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results